Associated Papers
A prospective, multicenter, comprehensive genomic profile signature study in patients with EGFR-mutant advanced non-small cell lung cancer at the first-line treatment failure of osimertinib.
Shi Y et al.
Signal Transduction and Targeted Therapy, 2025
Unveiling the role of PIK3R1 in cancer: A comprehensive review of regulatory signaling and therapeutic implications.
Gupta I et al.
Seminars in Cancer Biology, 2024
Negative Hyperselection of Resistance Mutations for Panitumumab Maintenance in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa Phase II Trial, AIO KRK 0212).
Stahler A et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2024
PI3K Mutation Profiles on Exons 9 (E545K and E542K) and 20 (H1047R) in Mexican Patients With HER-2 Overexpressed Breast Cancer and Its Relevance on Clinical-Pathological and Survival Biological Effects.
Nieto-Coronel T et al.
International Journal of Breast Cancer, 2024
Genetics of brain arteriovenous malformations and cerebral cavernous malformations.
Hongo H et al.
Journal of Human Genetics, 2023
The Genetic Architecture of Vascular Anomalies: Current Data and Future Therapeutic Perspectives Correlated with Molecular Mechanisms.
Butnariu LI et al.
International Journal of Molecular Sciences, 2022
Mutations in TP53 and PIK3CA genes in hepatocellular carcinoma patients are associated with chronic Schistosomiasis.
AlGabbani Q
Saudi Journal of Biological Sciences, 2022
SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study).
Langer CJ et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2019
Cancer-Associated PIK3CA Mutations in Overgrowth Disorders.
Madsen RR et al.
Trends in Molecular Medicine, 2018
Correlation between circulating cell-free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA-mutated metastatic breast cancer.
Kodahl AR et al.
Molecular Oncology, 2018
Racial Disparities in the Molecular Landscape of Cancer.
Heath EI et al.
Anticancer Research, 2018
Phase II basket trial of perifosine monotherapy for recurrent gynecologic cancer with or without PIK3CA mutations.
Hasegawa K et al.
Investigational New Drugs, 2017
PIK3CA mutations in HER2-positive Breast Cancer Patients; Frequency and Clinicopathological Perspective in Egyptian Patients
Elwy F et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2017
Clinical implications of routine genomic mutation sequencing in PIK3CA/AKT1 and KRAS/NRAS/BRAF in metastatic breast cancer.
Cejalvo JM et al.
Breast Cancer Research and Treatment, 2016
Improved survival associated with somatic PIK3CA mutations in copy-number low endometrioid endometrial adenocarcinoma.
Lin DI
Oncology Letters, 2015
Molecular profiling of infiltrating urothelial carcinoma of bladder and nonbladder origin.
Millis SZ et al.
Clinical Genitourinary Cancer, 2015
Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study.
Papaxoinis G et al.
Plos One, 2015
Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors.
Ducker GS et al.
Oncogene, 2014
Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells.
Rexer BN et al.
Breast Cancer Research : Bcr, 2014
An integrative analysis of PIK3CA mutation, PTEN, and INPP4B expression in terms of trastuzumab efficacy in HER2-positive breast cancer.
Sueta A et al.
Plos One, 2014
The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas.
Anderson RT et al.
Molecular Cancer Therapeutics, 2013
The determinants of head and neck cancer: Unmasking the PI3K pathway mutations.
Giudice FS et al.
Journal of Carcinogenesis & Mutagenesis, 2013
A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma.
Bauman JE et al.
Oral Oncology, 2013
Analysis of PIK3CA exon 9 and 20 mutations in breast cancers using PCR-HRM and PCR-ARMS: correlation with clinicopathological criteria.
Harlé A et al.
Oncology Reports, 2013
Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer.
Atreya CE et al.
Investigational New Drugs, 2012
High-resolution melting analysis as a sensitive prescreening diagnostic tool to detect KRAS , BRAF , PIK3CA , and AKT1 mutations in formalin-fixed, paraffin-embedded tissues.
Ney JT et al.
Archives of Pathology & Laboratory Medicine, 2012
PI3K expression and PIK3CA mutations are related to colorectal cancer metastases.
Zhu YF et al.
World Journal of Gastroenterology, 2012
Somatic mutations in PIK3CA and activation of AKT in intraductal tubulopapillary neoplasms of the pancreas.
Yamaguchi H et al.
The American Journal of Surgical Pathology, 2011
EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer.
Spindler KL et al.
Bmc Cancer, 2011
Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: in silico and biological evaluations.
Dan S et al.
Cancer Research, 2010
Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma.
Dunlap J et al.
Breast Cancer Research and Treatment, 2010
PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches.
Ligresti G et al.
Cell Cycle (georgetown, Tex.), 2009
Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population.
Abubaker J et al.
Oncogene, 2008
Effects of oncogenic p110alpha subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase.
Carson JD et al.
The Biochemical Journal, 2008
PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer.
Liedtke C et al.
Breast Cancer Research : Bcr, 2008